查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970839

腎衰竭治療市場－全球產業規模、佔有率、趨勢、機會與預測：按療法、最終用途、地區和競爭格局分類，2021-2031年

Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腎衰竭治療市場預計將從 2025 年的 1,117.8 億美元成長到 2031 年的 1,970.5 億美元，複合年成長率達到 9.91%。

該領域涵蓋多種用於治療急性或慢性腎衰竭的治療性介入和醫療程序，特別是腎臟移植和透析。市場成長的主要驅動力是全球生活型態相關疾病（如高血壓和糖尿病）盛行率的不斷上升，這些疾病是末期腎病變的主要病因。此外，老年人口的成長也推動了對長期腎臟替代療法的需求增加，從而確保了腹膜透析和血液透析兩種模式的穩定需求，使其免受市場暫時波動的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 1117.8億美元
市場規模：2031年 1970.5億美元
複合年成長率：2026-2031年 9.91%
成長最快的細分市場 透析
最大的市場 北美洲

然而，該行業面臨一個重大障礙：捐贈器官嚴重短缺。這嚴重限制了移植手術的數量，迫使患者依賴昂貴的維持性透析治療。這種供需失衡嚴重阻礙了根治性治療的進行。根據美國國家腎臟基金會的報告，到2024年，美國等待腎臟移植的人數將達到90,323人，凸顯了器官供應與日益成長的治療需求之間的巨大差距。

市場促進因素

全球高血壓和糖尿病盛行率的上升是腎衰竭治療市場的主要促進因素，直接增加了需要長期照護的人。隨著都市化和久坐生活方式的日益普及，這些慢性疾病的盛行率正在加速慢性腎臟病(CKD) 向末期腎功能衰竭(ESRD) 的進展，從而需要即時治療性介入。患者數量的持續成長反映在主要醫療服務提供者的運作指標中，凸顯了對腎臟護理的巨大需求。例如，DaVita 在 2025 年 2 月發布的 2024 年第四季財報中報告稱，其服務了約 281,100 名透析患者，這表明醫療保健系統面臨巨大壓力。同樣，醫療照護)報告的透析治療數量也印證了這一需求的規模，該公司在 2024 年於全球範圍內進行了約 4800 萬例透析治療。

同時，以改善病患生活品質為優先的科技進步和臨床方法正在推動居家透析療法的普及，重塑市場格局。遠端監測系統和攜帶式透析設備的創新使居家治療成為機構治療之外一種切實可行的更佳選擇，從而提高了患者的自主性並降低了感染風險。這種轉變為靈活治療方案的結構性趨勢得到了長期數據的支持。根據醫學教育研究所於2025年1月發布的《基於2024年美國腎臟資料系統年度資料的居家透析趨勢報告》，在分析期間，使用居家血液透析的患者比例增加了60%。為了抓住這一不斷成長的市場機遇，製造商正在迅速開發便捷易用的居家血液透析和腹膜透析解決方案。

市場挑戰

器官捐贈者嚴重短缺嚴重阻礙因素全球腎衰竭治療市場的發展，限制了可進行的移植手術數量。這種短缺阻礙了外科手術領域的擴張，並限制了移植後治療（市場價值鏈的關鍵組成部分）的引入。由於器官供應對腎病發病率的上升缺乏彈性，醫療機構無法擴大根治性手術的規模以滿足患者的需求。這種實際的限制造成了瓶頸，導致市場無法充分利用對永久性腎臟替代療法的需求。

因此，供需嚴重失衡導致等待時間延長，並使治療體系內的患者流動停滯不前。根據美國器官共用網路（UNOS）2024年的數據，上年度美國僅進行了約27,000例腎臟移植手術，僅滿足了總需求的一小部分。這種限制迫使患者繼續依賴維持性透析，阻礙了移植領域的發展，並妨礙了根治性治療的廣泛應用。

市場趨勢

GLP-1促效劑和SGLT2抑制劑的臨床應用不斷擴展，正從根本上改變治療格局，將治療重點從腎臟替代療法轉向延緩疾病進展。這一趨勢的特點是，能夠降低第2型糖尿病合併慢性腎臟病（CKD）患者腎損傷風險的藥物療法已被廣泛應用。隨著臨床指引不斷發展，更加重視器官保護，這些治療方法的處方箋激增，有效拓展了潛在市場，使其超越了傳統的血液透析患者群體。這一轉變得益於該領域強勁的財務表現。根據《製藥技術》（Pharmaceutical Technology）2025年8月刊的報導《諾和諾德的糖尿病和減重藥物銷售成長放緩》，該公司糖尿病和肥胖症治療產品組合（包括關鍵的腎臟保護藥物）的銷售額在2025年上半年成長了16%，達到1454億丹麥克朗。

同時，人工智慧（AI）在腎功能預測分析的應用，正透過數據驅動的風險評估和早期療育策略，變革病患管理模式。醫療機構正日益採用AI驅動的診斷平台來識別高風險患者並最佳化治療路徑，從而降低緊急透析的發生率。數位診斷工具報銷機制的改進加速了這項技術的普及，為臨床實踐中的應用提供了獎勵。近期揭露的財務數據也印證了這些先進分析解決方案日益成長的商業性可行性。根據Renalistics公司截至2025年3月的會計年度半年報，其商業保險覆蓋的檢測收入較上年度同期成長28%，反映出預後檢測在臨床實踐中的應用日益廣泛。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球腎衰竭治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（透析、腎臟移植、藥物治療、其他）
    • 依最終用途（醫院、專科診所、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美腎衰竭治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腎衰竭治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腎衰竭治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腎衰竭治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腎衰竭治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球腎衰竭治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • NIPRO
  • Fresenius Medical Care Holdings, Inc
  • Baxter International, Inc
  • Medtronic Plc
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • JMS Co.Ltd
  • Nikkiso Co., Ltd
  • AstraZeneca Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25375

The Global Renal Failure Treatment Market is projected to expand from USD 111.78 Billion in 2025 to USD 197.05 Billion by 2031, achieving a compound annual growth rate of 9.91%. This sector encompasses various therapeutic interventions and medical procedures, specifically kidney transplantation and dialysis, which are employed to manage acute or chronic renal function loss. The market's growth is fundamentally fueled by the increasing global prevalence of lifestyle-associated conditions, such as hypertension and diabetes, which are the leading causes of end-stage renal disease. Additionally, the rising geriatric demographic demands greater access to long-term renal replacement therapies, ensuring a steady demand for both peritoneal dialysis and hemodialysis modalities regardless of temporary market fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 111.78 Billion
Market Size 2031USD 197.05 Billion
CAGR 2026-20319.91%
Fastest Growing SegmentDialysis
Largest MarketNorth America

However, the industry confronts a significant obstacle regarding the critical scarcity of donor organs, which severely curtails the volume of transplant surgeries and necessitates a dependence on expensive maintenance dialysis. This imbalance between supply and demand creates a major bottleneck in delivering definitive curative care. As reported by the National Kidney Foundation, there were 90,323 patients on the kidney transplant waiting list in the United States in 2024, highlighting the profound disparity between organ availability and the escalating number of patients requiring treatment.

Market Driver

The rising global incidence of hypertension and diabetes serves as the primary catalyst for the renal failure treatment market, directly increasing the population requiring long-term care. As urbanization and sedentary lifestyles become more widespread, the prevalence of these chronic conditions accelerates the progression from Chronic Kidney Disease (CKD) to End-Stage Renal Disease (ESRD), requiring immediate therapeutic action. This continuous stream of patients is reflected in the operational metrics of major providers, underscoring the substantial demand for renal therapies. For instance, DaVita Inc. reported in their '4th Quarter 2024 Results' in February 2025 that they served approximately 281,100 dialysis patients, demonstrating the heavy burden on healthcare systems. Similarly, the scale of this demand is evident in the procedure volumes reported by Fresenius Medical Care, which performed around 48 million dialysis treatments globally in 2024.

Concurrently, the market is being reshaped by the increasing adoption of home-based dialysis modalities, driven by technological advancements and a clinical focus on improving patient quality of life. Innovations in remote monitoring systems and portable dialysis machines have made home treatment a practical and often preferred alternative to in-center care, offering patients greater independence and lower infection risks. Longitudinal data supports this structural shift toward flexible treatment options; according to the Medical Education Institute's January 2025 'Home Dialysis Updates from the 2024 USRDS Annual Data Report', the proportion of prevalent patients utilizing home hemodialysis grew by 60% during the analyzed period. Consequently, manufacturers are fast-tracking the development of user-friendly home hemodialysis and peritoneal solutions to capitalize on this expanding segment.

Market Challenge

The critical shortage of donor organs functions as a major restraint on the global renal failure treatment market by capping the volume of transplant procedures that can be performed. This scarcity limits the expansion of the surgical segment and restricts the uptake of post-transplant therapies, which are vital components of the market value chain. Because the supply of organs is inelastic compared to the rising incidence of renal disease, healthcare providers are unable to scale curative operations to meet patient needs. This physical limitation generates a bottleneck that prevents the market from fully capitalizing on the demand for permanent renal replacement solutions.

Consequently, the severe gap between supply and demand results in extended waiting periods that stall patient movement through the treatment ecosystem. Data from the United Network for Organ Sharing in 2024 revealed that only approximately 27,000 kidney transplants were performed in the United States during the preceding year, covering a small fraction of the total requirement. This limitation forces a continued dependence on maintenance dialysis, thereby hampering the growth of the transplant sector and stifling the potential for broader adoption of definitive curative treatments.

Market Trends

The expanded clinical application of GLP-1 agonists and SGLT2 inhibitors is fundamentally altering the treatment landscape by shifting focus from renal replacement to delaying disease progression. This trend is characterized by the widespread adoption of pharmaceutical interventions that mitigate the risk of adverse renal outcomes in patients with Type 2 diabetes and Chronic Kidney Disease (CKD). The market is seeing a surge in prescriptions for these therapies as clinical guidelines evolve to prioritize organ protection, effectively expanding the addressable market beyond traditional dialysis populations. This shift is substantiated by strong financial performance in the segment; according to Pharmaceutical Technology in August 2025, in the 'Novo Nordisk's diabetes and weight loss drug sales growth decelerates' article, sales for the company's diabetes and obesity care portfolio, which includes key renal-protective agents, grew 16% to DKK 145.4 billion in the first half of 2025.

Simultaneously, the integration of artificial intelligence for predictive renal analytics is transforming patient management through data-driven risk assessment and early intervention strategies. Healthcare providers are increasingly deploying AI-enabled diagnostic platforms to identify high-risk patients and optimize care pathways, thereby reducing the incidence of emergency dialysis starts. This technological adoption is being accelerated by improved reimbursement structures for digital diagnostic tools, which incentivizes clinical uptake. The growing commercial viability of these advanced analytics solutions is evident in recent financial disclosures; according to Renalytix plc's March 2025 'Half Year Report', the company recorded that commercial insurance reimbursed testing revenue increased by 28% compared to the first half of the previous fiscal year, reflecting the rising utilization of prognostic testing in clinical practice.

Key Market Players

  • NIPRO
  • Fresenius Medical Care Holdings, Inc
  • Baxter International, Inc
  • Medtronic Plc
  • B. Braun SE
  • Asahi Kasei Medical Co., Ltd.
  • AbbVie Inc.
  • JMS Co.Ltd
  • Nikkiso Co., Ltd
  • AstraZeneca Plc

Report Scope

In this report, the Global Renal Failure Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Failure Treatment Market, By Treatment

  • Dialysis
  • Kidney Transplantation
  • Drug Therapy
  • Others

Renal Failure Treatment Market, By End Use

  • Hospitals
  • Specialty Clinics
  • Others

Renal Failure Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Failure Treatment Market.

Available Customizations:

Global Renal Failure Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Renal Failure Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Dialysis, Kidney Transplantation, Drug Therapy, Others)
    • 5.2.2. By End Use (Hospitals, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Renal Failure Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Renal Failure Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Renal Failure Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Renal Failure Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End Use

7. Europe Renal Failure Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Renal Failure Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Renal Failure Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Renal Failure Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Renal Failure Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Renal Failure Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End Use

8. Asia Pacific Renal Failure Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Renal Failure Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Renal Failure Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Renal Failure Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Renal Failure Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Renal Failure Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Renal Failure Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Renal Failure Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Renal Failure Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Renal Failure Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End Use

10. South America Renal Failure Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Renal Failure Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Renal Failure Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Renal Failure Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Renal Failure Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NIPRO
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Fresenius Medical Care Holdings, Inc
  • 15.3. Baxter International, Inc
  • 15.4. Medtronic Plc
  • 15.5. B. Braun SE
  • 15.6. Asahi Kasei Medical Co., Ltd.
  • 15.7. AbbVie Inc.
  • 15.8. JMS Co.Ltd
  • 15.9. Nikkiso Co., Ltd
  • 15.10. AstraZeneca Plc

16. Strategic Recommendations

17. About Us & Disclaimer